We'll know a little more about the company's prospects by the end of the year.

The ability to precisely adjust the expression of genes inside the human body—ramping up protective ones and tamping down ...

CRISPR Therapeutics stock has climbed in the shorter term but still carries a heavy five year loss, and current valuation ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

Technologies like CRISPR are giving us new ways to create the dogs of our dreams — and a reason to reckon with our past ...

Gene editing reduced cholesterol by about 50% in an extremely small sample of patients over a year of follow-up, according to ...

Editas Medicine (EDIT) stays a Hold as EDIT-401 nears trials; preclinical 90%+ LDL-C reduction for HeFH, but dilution and competition loom—read more macroanalysis here.

The next six months may be decisive for the biotech.

Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026- -Phase 1a clinical ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

The CRISPR gene editing market is estimated at USD 4 billion in 2025 and is projected to reach USD 22 billion by 2035, expanding at a CAGR of 18.6% during the forecast period 2026–2035. The market is ...